Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Scott L. Friedman, Massimo Pinzani
Hepatology (2021) Vol. 75, Iss. 2, pp. 473-488
Open Access | Times Cited: 284

Showing 1-25 of 284 citing articles:

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases
Yumin Wang, Jing Hu, Shuang Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 71
The Evolution of Single-Cell RNA Sequencing Technology and Application: Progress and Perspectives
Shuo Wang, Si-Tong Sun, Xinyue Zhang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2943-2943
Open Access | Times Cited: 67
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Isabella Lurje, Nadine T. Gaisa, Ralf Weiskirchen, et al.
Molecular Aspects of Medicine (2023) Vol. 92, pp. 101191-101191
Closed Access | Times Cited: 63
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 57
Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
Liang Shan, Fengling Wang, Dandan Zhai, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114472-114472
Open Access | Times Cited: 42
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 41
Vicious Cycle‐Breaking Lipid Nanoparticles Remodeling Multicellular Crosstalk to Reverse Liver Fibrosis
Lingfeng Zhang, Wen‐Qi Deng, Qing‐Wen Huang, et al.
Advanced Materials (2024) Vol. 36, Iss. 16
Closed Access | Times Cited: 15
Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Hikmet Akkız, Robert K. Gieseler, Ali Canbay
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7873-7873
Open Access | Times Cited: 15
MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization
Jie Zhang, Yu Liu, Chien‐Jen Chen, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 43
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogramming
Morgane Mabire, Pushpa Hegde, Adel Hammoutène, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 36
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease
Timothy J. Kendall, Maria Jiménez Ramos, Frances Turner, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2939-2953
Open Access | Times Cited: 33
In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Young‐Sun Lee, Ekihiro Seki
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 16, Iss. 3, pp. 355-367
Open Access | Times Cited: 32
Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
Stefano Ballestri, Alessandro Mantovani, Maria Di Girolamo, et al.
Metabolism and Target Organ Damage (2023) Vol. 3, Iss. 1, pp. 1-1
Open Access | Times Cited: 27
Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases
Junyan Zhu, Sicong Wang, Dakai Yang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 27
The Origin and Fate of Liver Myofibroblasts
Hyun Young Kim, Sadatsugu Sakane, Álvaro Eguileor, et al.
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 17, Iss. 1, pp. 93-106
Open Access | Times Cited: 27
The role of N-glycosylation modification in the pathogenesis of liver cancer
Mengyu Hu, Rui Zhang, Jiaren Yang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 26
Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models
Elisabetta Caon, María Manuela Martins, Harry Hodgetts, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 941-956
Open Access | Times Cited: 13
Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis
Ming Kong, Junjing Zhou, Aoqi Kang, et al.
Gut (2024) Vol. 73, Iss. 5, pp. 810-824
Closed Access | Times Cited: 10
Pathophysiology and therapeutic options for cirrhotic portal hypertension
Sergi Guixé‐Muntet, Sergio Quesada‐Vázquez, Jordi Gracia‐Sancho
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 7, pp. 646-663
Closed Access | Times Cited: 10
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review)
Jiaqin Gao, Bin Zuo, Yang He
Molecular Medicine Reports (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 8
A machine learning based algorithm accurately stages liver disease by quantification of arteries
Zhengxin Li, Xin Sun, Zhimin Zhao, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients
Qiyao Wei, Jing Zhao
BMC Gastroenterology (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Lactucin alleviates liver fibrosis by regulating the TLR4-MyD88-MAPK/NF-κB signaling pathway through intestinal flora
Liping Zhu, Bo Lv, Yuefeng Gao, et al.
Archives of Biochemistry and Biophysics (2025), pp. 110341-110341
Closed Access | Times Cited: 1
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1778-1778
Open Access | Times Cited: 1
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top